Association between second-generation antipsychotics and newly diagnosed treated diabetes mellitus: Does the effect differ by dose?

BMC Psychiatry

Volumn 11, Issue , 2011, Pages

  Ulcickas Yood, Marianne ^a,b   DeLorenze, Gerald N ^c   Quesenberry Jr, Charles P ^c   Oliveria, Susan A ^a   Tsai, Ai Lin ^c   Kim, Edward ^d   Cziraky, Mark J ^e   McQuade, Robert D ^f   Newcomer, John W ^g   L'Italien, Gilbert J ^h,i  

^a EpiSource LLC   (United States)

^b BOSTON UNIVERSITY   (United States)

^c DIVISION OF RESEARCH   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

^e HEALTHCORE INC   (United States)

^f OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^g WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h BRISTOL MYERS SQUIBB   (United States)

ⁱ YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFECT; FEMALE; HAZARD RATIO; HEALTH CARE SYSTEM; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; RISK ASSESSMENT; ADOLESCENT; AGED; CHEMICALLY INDUCED DISORDER; MIDDLE AGED; PSYCHOSIS;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; DIABETES MELLITUS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHOTIC DISORDERS;

EID: 83455213656     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-11-197     Document Type: Article

References (16)

1. Stahl SM. Selecting an atypical antipsychotic by combining clinical experience with guidelines from clinical trials. J Clin Psychiatry 1999, 60(Suppl 10):31-41.
2. Association AD, Association AP, . Endocrinologists AAoC, Obesity NAAftSo Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 2004, 65(2):267-272. Endocrinologists AAoC, Obesity NAAftSo.
3. Association AD, Association AP, . Endocrinologists AAoC, Obesity NAAftSo Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004, 27(2):596-601. Endocrinologists AAoC, Obesity NAAftSo.
4. Buse JB, Cavazzoni P, Hornbuckle K, Hutchins D, Breier A, Jovanovic L. A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. Journal of clinical epidemiology 2003, 56(2):164-170. 10.1016/S0895-4356(02)00588-7, 12654411.
5. Caro JJ, Ward A, Levinton C, Robinson K. The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis. J Clin Psychiatry 2002, 63(12):1135-1139. 10.4088/JCP.v63n1208, 12523873.
6. Feldman PD, Hay LK, Deberdt W, Kennedy JS, Hutchins DS, Hay DP, Hardy TA, Hoffmann VP, Hornbuckle K, Breier A. Retrospective cohort study of diabetes mellitus and antipsychotic treatment in a geriatric population in the United States. Journal of the American Medical Directors Association 2004, 5(1):38-46. 10.1016/S1525-8610(04)70042-0, 14706127.
7. Fuller MA, Shermock KM, Secic M, Grogg AL. Comparative study of the development of diabetes mellitus in patients taking risperidone and olanzapine. Pharmacotherapy 2003, 23(8):1037-1043. 10.1592/phco.23.8.1037.32876, 12921249.
8. Ulcickas Yood M, deLorenze G, Quesenberry CP, Oliveria SA, Tsai A, Willey VJ, McQuade R, Newcomer JW, L'Italien G. The incidence of diabetes in atypical antipsychotic users differs according to agent--results from a multisite epidemiologic study. Pharmacoepidemiology and Drug Safety 2009, 18(9):791-799. 10.1002/pds.1781, 19526626.
9. Nielsen J, Skadhede S, Correll CU. Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naive schizophrenia patients. Neuropsychopharmacology 2010, 35(9):1997-2004. 10.1038/npp.2010.78, 3055629, 20520598.
10. Gianfrancesco F, Wang RH, Nasrallah HA. The influence of study design on the results of pharmacoepidemiologic studies of diabetes risk with antipsychotic therapy. Ann Clin Psychiatry 2006, 18(1):9-17.
11. Kessing LV, Thomsen AF, Mogensen UB, Andersen PK. Treatment with antipsychotics and the risk of diabetes in clinical practice. Br J Psychiatry 2010, 197(4):266-271. 10.1192/bjp.bp.109.076935, 20884948.
12. Citrome L, Reist C, Palmer L, Montejano L, Lenhart G, Cuffel B, Harnett J, Sanders KN. Dose trends for second-generation antipsychotic treatment of schizophrenia and bipolar disorder. Schizophr Res 2009, 108(1-3):238-244. 10.1016/j.schres.2008.11.017, 19106035.
13. Risperdal: Full U.S. Prescribing Information. , http://www.risperdal.com/risperdal/shared/pi/risperdal.pdf
14. Prescribing Information for Seroquel. , http://www.astrazeneca-us.com/cgi-bin/az_pi.cgi?product=seroquel&country=us&popup=no
15. Leslie DL, Mohamed S, Rosenheck RA. Off-label use of antipsychotic medications in the department of Veterans Affairs health care system. Psychiatr Serv 2009, 60(9):1175-1181. 10.1176/appi.ps.60.9.1175, 19723731.
16. Guo Z, L'Italien GJ, Jing Y, Baker RA, Forbes RA, Hebden T, Kim E. A real-world data analysis of dose effect of second-generation antipsychotic therapy on hemoglobin A1C level. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35(5):1326-1332. 10.1016/j.pnpbp.2011.03.020, 21515328.